Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET
Company Participants
Joey Perrone – SVP, Finance and IR
Jeremy Bender – CEO
Lauren Merendino – CCO
Charles York – COO and CFO
Conference Call Participants
Andrea Newkirk – Goldman Sachs
Tara Bancroft – TD Cowen
Joe Catanzaro – Piper Sandler
Alec Stranahan – Bank of America
Andres Maldonado – H.C. Wainwright
Operator
Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. Please be advised that this conference call is being recorded.
I would now like to turn the call over to Joey Perrone, Senior Vice President of Finance and Investor Relations. Please go ahead.
Joey Perrone
Thank you. Hello, everyone, and good afternoon. Welcome to Day One’s Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call. Earlier today, we issued a press release, which outlines the topics we plan to discuss today. You can access the press release and the slides to accompany this conference call on the Investors and Media section of our website at www.dayonebio.com. An audio webcast with the corresponding slides is also available on the website.
Before we get started, I’d like to remind everyone that some of the statements that we make on this call and information presented in the slide deck include forward-looking statements as outlined on Slide 2. Actual events and results could differ materially from those expressed or implied by any forward-looking statements. We encourage you to review the various risks, uncertainties and other factors included in our most recent filings with the SEC and any other future filings that we may make
